Form 4: Axsome Therapeutics Director Receives RSU Grant

Director Mark E. Saad was granted 1,721 restricted stock units as part of his compensation package with Axsome Therapeutics.

Summary

• Director Mark E. Saad acquired 1,721 restricted stock units (RSUs) on June 5, 2026.
• Each RSU represents a contingent right to receive one share of Axsome Therapeutics common stock.
• The grant is subject to a one-year vesting schedule, fully vesting on June 5, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Standard market risks associated with equity ownership and potential dilution upon future settlement of RSUs.

Future Outlook

The RSUs are scheduled to vest in full on the one-year anniversary of the grant date, June 5, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with standard corporate governance practices for mid-cap biotechnology companies.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 1,721 RSUs on June 5, 2027.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Director Compensation, Restricted Stock Units